INGN Inogen Inc

Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0001294133
AI RATING
SELL
75% Confidence

Investment Thesis

Inogen demonstrates strong top-line growth (+18.1% YoY) and maintains fortress-like balance sheet strength with $93.1M cash and negligible debt, but operationally deteriorates with negative operating income (-$9.3M), negative operating cash flow (-$6.7M), and negative free cash flow despite revenue expansion. The fundamental disconnect between 18% revenue growth and persistent unprofitability indicates operational leverage challenges or structural margin pressures that create unacceptable risk without clear evidence of profitability trajectory.

Strengths

  • + Strong revenue growth of 18.1% YoY demonstrates sustained market demand
  • + Excellent liquidity position with $93.1M cash and 3.1x current ratio provides operational flexibility
  • + Debt-free balance sheet ($80K long-term debt) with strong equity base ($182.9M) minimizes financial distress risk
  • + Improving loss trend with EPS improving 43.4% YoY suggests margin trajectory is turning
  • + Healthy gross margin of 44.5% indicates reasonable unit economics and pricing power

Risks

  • ! Operating unprofitability with -$9.3M operating income and -$8.3M net income despite revenue growth signals operational dysfunction
  • ! Negative operating cash flow of -$6.7M reveals core business is cash-consumptive, requiring balance sheet depletion to fund operations
  • ! Negative return on equity (-4.6%) and assets (-2.9%) shows inefficient capital deployment and value destruction for shareholders
  • ! Operating margin of -11% suggests fixed cost base is not absorbing into scaling revenue model as expected
  • ! Cash burn trajectory is unsustainable if profitability improvement does not materialize within 1-2 years

Key Metrics to Watch

Financial Metrics

Revenue
85.1M
Net Income
-8.3M
EPS (Diluted)
$-0.30
Free Cash Flow
-6.9M
Total Assets
285.9M
Cash
93.1M

Profitability Ratios

Gross Margin 44.5%
Operating Margin -11.0%
Net Margin -9.8%
ROE -4.6%
ROA -2.9%
FCF Margin -8.1%

Balance Sheet & Liquidity

Current Ratio
3.10x
Quick Ratio
2.70x
Debt/Equity
0.00x
Debt/Assets
36.0%
Interest Coverage
-1,556.00x
Long-term Debt
80.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T08:53:16.322439 | Data as of: 2026-03-31 | Powered by Claude AI